A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

Trial Details

NCT ID
NCT06644781
Phase
PHASE3
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Ifinatamab deruxtecan
  • Docetaxel
  • Paclitaxel
  • Irinotecan hydrochloride (HCl)
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Fullerton, California, United States|33.87029,-117.92534
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for randomization into the study:
  • Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
  • Has histologically or cytologically documented unresectable locally advanced or metastatic ESCC according to American Joint Committee on Cancer 8th…
  • Has disease progression post a platinum-based chemotherapy and an ICI treatment per global or local guidelines, with a maximum of 1 prior line of s…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →